Table 3.

Disease modifying therapeutic approaches for PSP based on their target etiopathogenic process.

Target	Reduction of abnormal PTMs	Blocking transcellular spread	Mitochondrial complex I enhancers	Autophagy enhancers	Microtubule stabilizers	Reduction of microglial activation and inflammation	Reduction of tau expression
Preclinical/Hypothetical	• Novel GSK3β inhibitors • Inhibitors of other kinases  • CDK5  • Brain specific calpain  • ROCK	• Novel anti-4R-tau antibodies				• Benfotiamine (NRF2-dependent genes expression enhancer) • 5-Lipoxygenase blockers	• Antisense oligonucleotides • RNA interference silencing of tau expression
Ongoing clinical trials	• ASN120290 • MK-8719	• BIIB092		• AZP2006	• TPI-287
Completed clinical trials	• Tideglusib • Sodium valproate • Lithium • Salsalate	• ABBV-8E12	• Coenzyme Q10 • α-lipolic acid with L-acetyl carnitine • Pyruvate with creatine and niacinamide	• Lithium	• Davunetide	• Salsalate